UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Chagas disease: Chronic Trypanosoma cruzi infection

Author
Caryn Bern, MD, MPH
Section Editor
Peter F Weller, MD, MACP
Deputy Editor
Elinor L Baron, MD, DTMH

INTRODUCTION

Chagas disease is caused by infection with the protozoan parasite Trypanosoma cruzi; the major manifestations are Chagas cardiomyopathy and gastrointestinal disease [1].

Issues related to the natural history, clinical manifestations, diagnosis, and management of chronic Chagas disease will be reviewed here. Issues related to acute and congenital Chagas infection are discussed separately. (See "Chagas disease: Acute and congenital Trypanosoma cruzi infection".)

Issues related to the epidemiology and prevention of Chagas disease are discussed separately. (See "Chagas disease: Epidemiology and prevention".)

Issues related to cardiac and gastrointestinal Chagas are discussed separately. (See "Chagas heart disease: Clinical manifestations and diagnosis" and "Chagas heart disease: Treatment and prognosis" and "Chagas gastrointestinal disease".)

NATURAL HISTORY

Overview — T. cruzi infection is characterized by two phases, acute and chronic (figure 1). The acute phase lasts 8 to 12 weeks after transmission. (See "Chagas disease: Acute and congenital Trypanosoma cruzi infection".)

             
To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Sep 2017. | This topic last updated: Sep 11, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
References
Top
  1. Bern C. Chagas' Disease. N Engl J Med 2015; 373:456.
  2. Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet 2010; 375:1388.
  3. Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA 2007; 298:2171.
  4. Dias JC, Ramos AN Jr, Gontijo ED, et al. [Brazilian Consensus on Chagas Disease, 2015]. Epidemiol Serv Saude 2016; 25:7.
  5. Marin-Neto JA, Bromberg-Marin G, Pazin-Filho A, et al. Cardiac autonomic impairment and early myocardial damage involving the right ventricle are independent phenomena in Chagas' disease. Int J Cardiol 1998; 65:261.
  6. Genovese O, Ballario C, Storino R, et al. Clinical manifestations of peripheral nervous system involvement in human chronic Chagas disease. Arq Neuropsiquiatr 1996; 54:190.
  7. Bern C. Chagas disease in the immunosuppressed host. Curr Opin Infect Dis 2012; 25:450.
  8. Martinez-Perez A, Norman FF, Monge-Maillo B, et al. An approach to the management of Trypanosoma cruzi infection (Chagas' disease) in immunocompromised patients. Expert Rev Anti Infect Ther 2014; 12:357.
  9. World Health Organization. Control of Chagas Disease: Second report of the WHO expert committee. WHO, Geneva 2002. http://apps.who.int/iris/bitstream/10665/42443/1/WHO_TRS_905.pdf (Accessed on August 01, 2017).
  10. Sosa-Estani S, Gamboa-León MR, Del Cid-Lemus J, et al. Use of a rapid test on umbilical cord blood to screen for Trypanosoma cruzi infection in pregnant women in Argentina, Bolivia, Honduras, and Mexico. Am J Trop Med Hyg 2008; 79:755.
  11. Umezawa ES, Bastos SF, Camargo ME, et al. Evaluation of recombinant antigens for serodiagnosis of Chagas' disease in South and Central America. J Clin Microbiol 1999; 37:1554.
  12. Verani JR, Seitz A, Gilman RH, et al. Geographic variation in the sensitivity of recombinant antigen-based rapid tests for chronic Trypanosoma cruzi infection. Am J Trop Med Hyg 2009; 80:410.
  13. Tarleton RL, Reithinger R, Urbina JA, et al. The challenges of Chagas Disease-- grim outlook or glimmer of hope. PLoS Med 2007; 4:e332.
  14. Leiby DA, Wendel S, Takaoka DT, et al. Serologic testing for Trypanosoma cruzi: comparison of radioimmunoprecipitation assay with commercially available indirect immunofluorescence assay, indirect hemagglutination assay, and enzyme-linked immunosorbent assay kits. J Clin Microbiol 2000; 38:639.
  15. Silveira-Lacerda EP, Silva AG, Junior SF, et al. Chagas' disease: application of TESA-blot in inconclusive sera from a Brazilian blood bank. Vox Sang 2004; 87:204.
  16. Lopez-Velez R, Norman FF, Bern C. American Trypanosomiasis (Chagas Disease). In: Hunter's Tropical Medicine and Emerging Infectious Desease, 9th ed, Magill AJ, Ryan ET, Solomon T, Hill DR (Eds), Saunders, Philadelphia 2013. p.725.
  17. Gorlin J, Rossmann S, Robertson G, et al. Evaluation of a new Trypanosoma cruzi antibody assay for blood donor screening. Transfusion 2008; 48:531.
  18. Ramírez JD, Guhl F, Umezawa ES, et al. Evaluation of adult chronic Chagas' heart disease diagnosis by molecular and serological methods. J Clin Microbiol 2009; 47:3945.
  19. InBios. FDA Clears First Point of Care Rapid Diagnostic Test Kit for Chagas Disease. Seattle, 2016. http://www.prweb.com/releases/2016/12/prweb13938661.htm (Accessed on August 01, 2017).
  20. Shah V, Ferrufino L, Gilman RH, et al. Field evaluation of the InBios Chagas detect plus rapid test in serum and whole-blood specimens in Bolivia. Clin Vaccine Immunol 2014; 21:1645.
  21. Schijman AG, Bisio M, Orellana L, et al. International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. PLoS Negl Trop Dis 2011; 5:e931.
  22. Qvarnstrom Y, Schijman AG, Veron V, et al. Sensitive and specific detection of Trypanosoma cruzi DNA in clinical specimens using a multi-target real-time PCR approach. PLoS Negl Trop Dis 2012; 6:e1689.
  23. Williams JE. Leishmania and Trypanosoma. In: Medical Parasitology: A Practical Approach, Gillespie SH, Hawkey PM (Eds), Oxford University Press, Oxford, UK 1995. p.151.
  24. Bern C. Antitrypanosomal therapy for chronic Chagas' disease. N Engl J Med 2011; 364:2527.
  25. Pérez-Molina JA, Molina I. Chagas disease. Lancet 2017.
  26. Lázzari JO, Pereira M, Antunes CM, et al. Diagnostic electrocardiography in epidemiological studies of Chagas' disease: multicenter evaluation of a standardized method. Rev Panam Salud Publica 1998; 4:317.
  27. de Andrade AL, Zicker F, de Oliveira RM, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996; 348:1407.
  28. Sosa Estani S, Segura EL, Ruiz AM, et al. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg 1998; 59:526.
  29. Altcheh J, Moscatelli G, Moroni S, et al. Adverse events after the use of benznidazole in infants and children with Chagas disease. Pediatrics 2011; 127:e212.
  30. Pérez-Molina JA, Pérez-Ayala A, Moreno S, et al. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. J Antimicrob Chemother 2009; 64:1139.
  31. Reyes PA, Vallejo M. Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection). Cochrane Database Syst Rev 2005; :CD004102.
  32. Villar JC, Marin-Neto JA, Ebrahim S, Yusuf S. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst Rev 2002; :CD003463.
  33. Pinazo MJ, Thomas MC, Bua J, et al. Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review. Expert Rev Anti Infect Ther 2014; 12:479.
  34. Fabbro DL, Danesi E, Olivera V, et al. Trypanocide treatment of women infected with Trypanosoma cruzi and its effect on preventing congenital Chagas. PLoS Negl Trop Dis 2014; 8:e3312.
  35. Molina I, Gómez i Prat J, Salvador F, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. N Engl J Med 2014; 370:1899.
  36. Morillo CA, Waskin H, Sosa-Estani S, et al. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial. J Am Coll Cardiol 2017; 69:939.
  37. Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006; 144:724.
  38. Rassi A Jr, Marin JA Neto, Rassi A. Chronic Chagas cardiomyopathy: a review of the main pathogenic mechanisms and the efficacy of aetiological treatment following the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial. Mem Inst Oswaldo Cruz 2017; 112:224.
  39. Wegner DH, Rohwedder RW. Experience with nifurtimox in chronic Chagas' infection. Preliminary report. Arzneimittelforschung 1972; 22:1635.
  40. Murcia L, Simón M, Carrilero B, et al. Treatment of Infected Women of Childbearing Age Prevents Congenital Trypanosoma cruzi Infection by Eliminating the Parasitemia Detected by PCR. J Infect Dis 2017; 215:1452.
  41. Morillo CA, Marin-Neto JA, Avezum A, et al. Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med 2015; 373:1295.
  42. Rassi A Jr, Rassi A, Little WC. Chagas' heart disease. Clin Cardiol 2000; 23:883.
  43. de Oliveira RB, Troncon LE, Dantas RO, Menghelli UG. Gastrointestinal manifestations of Chagas' disease. Am J Gastroenterol 1998; 93:884.
  44. Molina I, Salvador F, Sánchez-Montalvá A. Posaconazole versus benznidazole for chronic Chagas' disease. N Engl J Med 2014; 371:966.
  45. Ramírez JC, Cura CI, da Cruz Moreira O, et al. Analytical Validation of Quantitative Real-Time PCR Methods for Quantification of Trypanosoma cruzi DNA in Blood Samples from Chagas Disease Patients. J Mol Diagn 2015; 17:605.
  46. Chatelain E. Chagas disease drug discovery: toward a new era. J Biomol Screen 2015; 20:22.